Definitive Healthcare (DH) Set to Post Earnings on Thursday

Posted by on Nov 3rd, 2026

Definitive Healthcare (NASDAQ:DH – Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Definitive Healthcare to post earnings of $0.04 per share and revenue of $54.58 million for the quarter. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 5:00 PM ET.

Definitive Healthcare (NASDAQ:DH – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a negative net margin of 72.28% and a positive return on equity of 3.55%. The company had revenue of $55.20 million for the quarter, compared to the consensus estimate of $55.47 million. On average, analysts expect Definitive Healthcare to post $0.06 EPS for the current fiscal year and $0.04 EPS for the next fiscal year.

Definitive Healthcare Stock Performance

DH opened at $1.13 on Tuesday. The firm has a 50 day moving average of $0.99 and a two-hundred day moving average of $1.09. The firm has a market capitalization of $120.62 million, a PE ratio of -0.71, a P/E/G ratio of 14.07 and a beta of 1.40. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of 0.81. Definitive Healthcare has a 12-month low of $0.61 and a 12-month high of $3.00.

Analyst Ratings Changes

DH has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a report on Monday, August 31st. Morgan Stanley reduced their price objective on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating for the company in a research note on Tuesday, August 11th. BTIG Research reissued a “neutral” rating on shares of Definitive Healthcare in a report on Friday, September 4th. Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday, September 13th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $1.00 target price on shares of Definitive Healthcare in a report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $1.47.

Check Out Our Latest Analysis on DH

Definitive Healthcare Company Profile

(Get Free Report)

Definitive Healthcare Corp. (NASDAQ: DH) provides data, analytics and commercial intelligence solutions for the healthcare industry. Its platform is designed to help organizations understand healthcare markets, identify business opportunities and make data-driven decisions.

The company serves pharmaceutical and biotechnology companies, medical device manufacturers, healthcare providers, hospitals and health systems, and other healthcare services organizations. Its offerings include information on healthcare providers and organizations, market intelligence, sales and marketing analytics, clinical trial insights, and tools that support commercial planning, market access and customer engagement.

Definitive Healthcare was founded in 2011 and became a publicly traded company in 2021.

Read More

Earnings History for Definitive Healthcare (NASDAQ:DH)

Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.